Also that day, Orchid said it has extended the time during which Chairman George Poste will serve as interim CEO. Poste will now man the helm until the company files its quarterly earnings report for the first quarter of 2006 and amends earnings reports for the second and third quarters of 2005. As that time, Thomas Bologna will formally become Orchid's president and CEO.
Previously, Orchid said
Epidauros Biotechnology has appointed Michael Lutz as its new CEO, replacing Manfred Zoltobrocki. Lutz joins Epidauros from SuNyx where he most recently worked as CEO and sold its Bioanalytics business to Qiagen. He received his PhD in bio-organic chemistry from the ETH in
Jorge Leon has become a member of CytoCore's medical advisory board, and
MDS has hired David Spaight as president of MDS Pharma Services, effective immediately. Most recently, Spaight served as senior vice president of global sales and marketing at Fisher Scientific Products. He has a BS in chemistry and an MBA from the
Tom Scholl has been hired by Genzyme Genetics as vice president of technology and development. He comes to Genzyme from Myriad Genetic Laboratories, where he was vice president of technology development.
Scholl has a PhD in molecular and cell biology from Pennsylvania State University, and BSs in microbiology from
Eksigent Technologies has hired David Weber as its new CEO and president. Weber, who also becomes a director, joins the company from Stratagene, where he was vice president of global marketing and business.
The Critical Path Institute has appointed Ellen Feigal as its new director of medical devices and imaging. Feigal is on sabbatical from TGen, where she is vice president of clinical sciences and deputy scientific director.
Feigal has a BS in biology and an MS in molecular biology and biochemistry from the